ASX:EXL

Stock Analysis Report

Executive Summary

Elixinol Global Limited, through its subsidiaries, manufactures and distributes industrial hemp-based dietary supplements and skincare products.

Snowflake

Fundamentals

Excellent balance sheet with high growth potential.

Risks

  • Elixinol Global has significant price volatility in the past 3 months.
  • Elixinol Global is covered by less than 3 analysts.

Share Price & News

How has Elixinol Global's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.6%

ASX:EXL

-8.5%

AU Personal Products

-1.7%

AU Market


1 Year Return

82.7%

ASX:EXL

-36.5%

AU Personal Products

1.5%

AU Market

EXL outperformed the Personal Products industry which returned -37.9% over the past year.

EXL outperformed the Market in Australia which returned 2.1% over the past year.


Share holder returns

EXLIndustryMarket
7 Day-5.6%-8.5%-1.7%
30 Day-35.6%-18.8%-3.2%
90 Day-52.5%-20.3%-0.1%
1 Year82.7%82.7%-35.2%-36.5%7.3%1.5%
3 Yearn/a-37.1%-42.5%30.7%13.8%
5 Yearn/a23.5%-0.06%37.6%7.0%

Price Volatility Vs. Market

How volatile is Elixinol Global's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Elixinol Global undervalued based on future cash flows and its price relative to the stock market?

2.19x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Elixinol Global's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Elixinol Global's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Elixinol Global is loss making, we can't compare its value to the Oceania Personal Products industry average.

Elixinol Global is loss making, we can't compare the value of its earnings to the Australia market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Elixinol Global, we can't assess if its growth is good value.


Price Based on Value of Assets

Elixinol Global is good value based on assets compared to the AU Personal Products industry average.


Next Steps

Future Growth

How is Elixinol Global expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

88.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Elixinol Global's revenue is expected to grow significantly at over 20% yearly.

Elixinol Global's earnings are expected to grow significantly at over 20% yearly.

Elixinol Global's revenue growth is expected to exceed the Australia market average.

Elixinol Global's earnings growth is expected to exceed the Australia market average.

Elixinol Global's earnings growth is expected to exceed the low risk savings rate of 2.3%.


Earnings per Share Growth Estimates


Future Return on Equity

Elixinol Global is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Elixinol Global performed over the past 5 years?

89.4%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Elixinol Global does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Elixinol Global's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Elixinol Global's 1-year growth to the Global Personal Products industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Elixinol Global has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Elixinol Global has efficiently used its assets last year compared to the Oceania Personal Products industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Elixinol Global improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Elixinol Global's financial position?


Financial Position Analysis

Elixinol Global is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Elixinol Global's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Elixinol Global's level of debt (0.2%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Elixinol Global's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 227.8x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Elixinol Global has sufficient cash runway for more than 3 years based on current free cash flow.

Elixinol Global has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 135% each year.


Next Steps

Dividend

What is Elixinol Global's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Elixinol Global's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Elixinol Global's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Elixinol Global has not reported any payouts.

Unable to verify if Elixinol Global's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Elixinol Global has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Elixinol Global's salary, the management and board of directors tenure and is there insider trading?

0.08yrs

Average management tenure


CEO

Stratos Karousos 0

0.1yrs

Tenure

AU$99,716

Compensation

Mr. Stratos Karousos has been Chief Executive Officer and Director of Elixinol Global Ltd. since July 16, 2019 and served as its Chief Commercial & Legal Officer since April 2019 until July 16, 2019. Mr. K ...


Management Age and Tenure

0.08yrs

Average Tenure

The average tenure for the Elixinol Global management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.0yrs

Average Tenure

The average tenure for the Elixinol Global board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Gabriel Ettenson

    Global Chief Technology Officer

    • Tenure: 0.1yrs
    • Compensation: AU$384.77k
  • Ron Dufficy

    CFO & Company Secretary

    • Tenure: 0.0yrs
    • Compensation: AU$454.87k
  • Paul Benhaim

    Co-Founder

    • Tenure: 1.9yrs
    • Compensation: AU$507.57k
  • Stratos Karousos

    CEO & Director

    • Tenure: 0.1yrs
    • Compensation: AU$99.72k
  • Kim Bradley-Ware

    Joint Company Secretary

    • Tenure: 0.6yrs
  • Makoto Matsumaru

    President of Hemp Foods Japan Co.

    • Tenure: 0.0yrs
  • Glen Zurcher

    Account Director of Investor Relations Department

    • Tenure: 0.0yrs
  • Greg Smith

    Global Chief Information Officer

    • Tenure: 0.1yrs
  • Leif Harrison

    CEO of America

    • Tenure: 0.1yrs
  • Ali Atcha

    Chief Executive Officer of Europe & UK

    • Tenure: 0.1yrs

Board Members

  • Andrew Duff (58yo)

    Independent Non-Executive Chairman

    • Tenure: 1.8yrs
  • Greg Ellery

    Non-Executive Director

    • Tenure: 0.3yrs
  • Paul Benhaim

    Co-Founder

    • Tenure: 1.9yrs
    • Compensation: AU$507.57k
  • Stratos Karousos

    CEO & Director

    • Tenure: 0.1yrs
    • Compensation: AU$99.72k

Company Information

Elixinol Global Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Elixinol Global Limited
  • Ticker: EXL
  • Exchange: ASX
  • Founded:
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: AU$347.493m
  • Shares outstanding: 137.89m
  • Website: https://www.elixinolglobal.com

Number of Employees


Location

  • Elixinol Global Limited
  • Gateway Tower
  • Level 36
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EXLASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJan 2018
EXLCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJan 2018
ELLX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 2018
E8MDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 2018

Biography

Elixinol Global Limited, through its subsidiaries, manufactures and distributes industrial hemp-based dietary supplements and skincare products. The company distributes hemp-derived cannabidiol products in ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 10:40
End of Day Share Price2019/08/21 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.